



## MEMORANDUM OF UNDERSTANDING EXECUTIVE SUMMARY

### MEMORANDUM OF UNDERSTANDING

BETWEEN

Valneva UK Ltd

AND

*“Pharmavaccs”*

FOR

Valneva in Partnership (VIP)

**Project Title:** Valneva in Partnership (VIP)

#### **Background:**

The objectives of the Valneva in Partnership (VIP) project are to make comprehensive and clinically robust travel health available to all through:



#### **Awareness**

Increase awareness of travel-related health risks and encourage travellers to seek professional advice before travelling



#### **Access**

Improve accessibility and convenience for travellers seeking advice by supporting the development and expansion of clinics offering comprehensive, high quality and clinically robust travel health services



#### **Advice**

Support HCPs to effectively communicate the benefits of travel health advice to increase the number of travellers protected

#### **Valneva in Partnership (VIP) programme**

The Valneva in Partnership (VIP) programme has been developed to address the three above mentioned areas by partnering with healthcare professionals and providers to develop and enhance their travel health offer.

The VIP programme is designed to both highlight elements of a travel service that could be improved, but also to introduce alternative ways of working and with Valneva UK's support will lead to the growth of a travel service. The VIP programme is designed to look at and support all elements of a travel service and is not limited to Valneva UK assets.

**Project:**

“Pharmavaccs” is keen to develop travel services through its pharmacies/clinics. To help address the problems of travel health awareness, travel health service access, and travel health advice quality. “Pharmavaccs” wishes to participate in Valneva’s VIP programme in order to enhance its possibility to create awareness of risk and illness associated with long distance travels and to provide travellers with good travel health advice. Valneva is willing to assist “Pharmavaccs” by offering “Pharmavaccs” to participate in Valneva’s VIP programme.

**Contributions of the Parties**

Valneva will supply the following assets to assist “Pharmavaccs” in its efforts to develop its travel services for the benefit of travellers:

Disease Awareness Materials Neva Online Training Training Events Beware of the Bugs Clinic Finder Clinic Set-up Support Documents Operational Support Choose an item.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All other outgoings concerned with the establishment or improvement of a travel health service are met by “Pharmavaccs” .

**The objectives of the Project are to:**

- To improve accessibility of travel health services and health care advice
- Train healthcare professionals (HCPs) in travel health to improve advice
- Improve disease awareness through HCP training and the provision of compliant and effective disease awareness materials
- Ensure compliant and ethical joint working
- To reduce the burden of travellers returning to the UK with a travel related disease

**General benefits:**

- Collaboration will benefit Valneva and “Pharmavaccs” through improved reputation of both organisations’ ability to work in partnership for the benefit of travellers’ outcomes and experience after getting adequate health care advice which in the end will lead to reduce NHS burden.

**Benefits for travellers:**

- To improve awareness of travel diseases to reduce travel related morbidity in travellers
- To improve access to ensure a greater coverage of travel health medicine to prevent illness in travellers
- To better inform patients through accessible quality advice
- To better inform travellers of travel-related risks

**Benefits for Valneva UK:**

- “Pharmavaccs” will contribute in creating awareness for illnesses related to Valneva’s core business

[A small proportion of vaccines accessed after travel health consultations may be Valneva products]

**Benefits for “Pharmavaccs”**

- The development of a deeper insight into the travel health market and with increasing coverage, the reputation of “Pharmavaccs” will improve, cementing its market share

Job ref:

Date of Preparation: Monday, 01 June 2020